Cubist Systematic Strategies LLC Has $256,000 Stock Holdings in FibroGen, Inc. (NASDAQ:FGEN)

Cubist Systematic Strategies LLC grew its holdings in FibroGen, Inc. (NASDAQ:FGEN) by 3,906.9% in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 287,332 shares of the biopharmaceutical company’s stock after buying an additional 280,161 shares during the quarter. Cubist Systematic Strategies LLC owned 0.29% of FibroGen worth $256,000 as of its most recent filing with the SEC.

Other hedge funds also recently made changes to their positions in the company. Alpine Global Management LLC acquired a new position in shares of FibroGen in the 1st quarter valued at $25,000. Delap Wealth Advisory LLC bought a new stake in shares of FibroGen in the 1st quarter worth about $27,000. Point72 DIFC Ltd grew its holdings in shares of FibroGen by 734.2% in the 2nd quarter. Point72 DIFC Ltd now owns 52,254 shares of the biopharmaceutical company’s stock worth $47,000 after purchasing an additional 45,990 shares during the last quarter. Doheny Asset Management CA bought a new stake in shares of FibroGen in the 2nd quarter worth about $48,000. Finally, Accel Wealth Management grew its holdings in shares of FibroGen by 117.5% in the 2nd quarter. Accel Wealth Management now owns 95,600 shares of the biopharmaceutical company’s stock worth $85,000 after purchasing an additional 51,645 shares during the last quarter. Institutional investors and hedge funds own 72.71% of the company’s stock.

FibroGen Stock Performance

FGEN opened at $0.34 on Tuesday. The firm’s 50-day simple moving average is $0.39 and its 200-day simple moving average is $0.89. FibroGen, Inc. has a twelve month low of $0.30 and a twelve month high of $2.93. The firm has a market cap of $34.13 million, a price-to-earnings ratio of -0.14 and a beta of 0.70.

FibroGen (NASDAQ:FGEN) last issued its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.09. The company had revenue of $50.64 million for the quarter, compared to the consensus estimate of $33.00 million. During the same period in the prior year, the company earned ($0.65) EPS. As a group, sell-side analysts anticipate that FibroGen, Inc. will post -0.91 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, StockNews.com started coverage on shares of FibroGen in a report on Sunday. They issued a “hold” rating on the stock.

FibroGen Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.